H
HemCon Medical Technologies
HemCon Medical Technologies, Inc was built on a simple premise – to save lives
About HemCon Medical Technologies
Tricol Biomedical, formerly known as HemCon Medical Technologies, operates as a specialized medical device company focused on hemostatic and wound care management. The company was originally founded in 2001, with HemCon's co-founders including Dr. William "Bill" Wiesmann and Kenton Gregory. Dr. Wiesmann, a former U.S. Army medical researcher, leveraged his extensive experience in combat casualty care to spearhead the development of the company's core technology. His work was driven by the long-standing military need for a solution to control severe bleeding on the battlefield.
The company's history is rooted in a partnership with the U.S. Army, which began in 2001 to design a life-saving hemostatic dressing. This collaboration led to the creation of the HemCon bandage, which was released in 2003 and became the first advanced dressing of its kind used for rapid hemorrhage control in combat situations. The technology was recognized as one of the U.S. Army's "Top 10 Greatest Inventions" for its impact. In April 2016, the assets of HemCon Medical Technologies, including the brand name and product line, were acquired by Tricol International Group Ltd., and the company began operating as Tricol Biomedical, Inc. This acquisition was intended to merge Tricol's expertise in chitosan materials with HemCon's established presence in the wound care market, aiming for growth in surgical and chronic wound care sectors.
Tricol Biomedical develops, manufactures, and markets its products, which serve medical professionals in hospitals, military organizations, first responders, and consumers. The business model involves direct sales and partnerships with distributors, such as a significant 2021 agreement with Medline Industries, to broaden the reach of its product families across North America. The company's core product offering is based on its proprietary Chito+ technology, which utilizes chitosan, a naturally occurring polysaccharide derived from shrimp shells. The polycationic (positive) charge of the chitosan facilitates a strong bond with negatively charged tissues and blood cells, which helps to quickly seal wounds and control bleeding independently of the body's natural clotting process. The material also serves as an antibacterial barrier. The product portfolio is segmented into three main categories: Trauma Management for battlefield and pre-hospital settings; Procedural Care for controlling bleeding in clinical and surgical environments; and Consumer Self-Care for home use. Products are marketed under brand names including HemCon®, OneStop™, and m.doc®.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2001
- Headquarters
- Portland, United States
- Employees
- 14
- Open positions
- None listed
- Dealroom signal
- 42.1/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Mar 2007 | $12M | $48M | Camden Partners · Torch Hill Investment Partners | — |
Growth signals
Latest recorded traffic for HemCon Medical Technologies is 1.4K monthly website visits, up 16.7% over the last three months. HemCon Medical Technologies's team grew 7.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
HemCon Medical Technologies in the Portland ecosystem
The HemCon Medical Technologies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later2 investors entered at this stage
Camden Partners
Torch Hill Investment Partners
Other known investors1 additional known investor
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about HemCon Medical Technologies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See HemCon Medical Technologies’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






